EMJ Oncology 9 [Supplement 7] . 2021

Journal Info

In this supplement to EMJ Oncology, four leading researchers, Frederik Marmé, Christina Fotopoulou, Ursula Matulonis, and David Bowtell, discussed the impact of late diagnosis and delayed treatment on patient outcomes in ovarian cancer, genetic screening, and risk-reduction strategies.  The evolving landscape of homologous recombination deficiency (HRD) testing and the importance of HRD testing at diagnosis are also explored.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?